Najat Ziyadeh

Summary

Affiliation: Cancer Prevention Program
Country: USA

Publications

  1. ncbi The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database
    Najat Ziyadeh
    i3 Drug Safety, Waltham, Massachusetts 02451, USA
    Clin Ther 31:2665-77. 2009
  2. ncbi Coronary heart disease outcomes in patients receiving antidiabetic agents
    Andrew T McAfee
    i3 Drug Safety, Newton, Massachusetts 02451, USA
    Pharmacoepidemiol Drug Saf 16:711-25. 2007
  3. ncbi A matched cohort study of the risk of cancer in users of becaplermin
    Najat Ziyadeh
    Ingenix, i3 Drug Safety, Waltham, Massachusetts, USA
    Adv Skin Wound Care 24:31-9. 2011
  4. ncbi Incidence of allergic reactions associated with antibacterial use in a large, managed care organisation
    Catherine B Johannes
    i3 Drug Safety, Waltham, MA 02451, USA
    Drug Saf 30:705-13. 2007
  5. ncbi Linkage of routinely collected oncology clinical data with health insurance claims data--an example with aromatase inhibitors, tamoxifen, and all-cause mortality
    David D Dore
    Departments of Health Services, Policy and Practice and Epidemiology, Program in Public Health, The Warren Alpert Medical School of Brown University, Providence, RI, USA
    Pharmacoepidemiol Drug Saf 21:29-36. 2012

Collaborators

Detail Information

Publications5

  1. ncbi The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database
    Najat Ziyadeh
    i3 Drug Safety, Waltham, Massachusetts 02451, USA
    Clin Ther 31:2665-77. 2009
    ..Although recent meta-analyses suggest there is an increased risk of myocardial infarction (MI) among rosiglitazone users, these findings were not supported by data from other studies...
  2. ncbi Coronary heart disease outcomes in patients receiving antidiabetic agents
    Andrew T McAfee
    i3 Drug Safety, Newton, Massachusetts 02451, USA
    Pharmacoepidemiol Drug Saf 16:711-25. 2007
    ..There is conflicting evidence on the reduction of cardiovascular risk in diabetic patients treated with oral antidiabetic agents...
  3. ncbi A matched cohort study of the risk of cancer in users of becaplermin
    Najat Ziyadeh
    Ingenix, i3 Drug Safety, Waltham, Massachusetts, USA
    Adv Skin Wound Care 24:31-9. 2011
    ..8 (95% confidence interval [CI], 0.6-12.8). The authors aimed to further investigate any association between becaplermin use and the occurrence of cancer by following a large cohort of patients in a clinical practice setting...
  4. ncbi Incidence of allergic reactions associated with antibacterial use in a large, managed care organisation
    Catherine B Johannes
    i3 Drug Safety, Waltham, MA 02451, USA
    Drug Saf 30:705-13. 2007
    ..Data on the incidence of serious allergic reactions to fluoroquinolone antibacterials are mainly derived from spontaneous reports that cannot be used to accurately estimate incidence...
  5. ncbi Linkage of routinely collected oncology clinical data with health insurance claims data--an example with aromatase inhibitors, tamoxifen, and all-cause mortality
    David D Dore
    Departments of Health Services, Policy and Practice and Epidemiology, Program in Public Health, The Warren Alpert Medical School of Brown University, Providence, RI, USA
    Pharmacoepidemiol Drug Saf 21:29-36. 2012
    ..Our objective was to evaluate routinely collected cancer clinical data for adjustment of confounding using an example evaluation of mortality associated with aromatase inhibitors and tamoxifen...